Pfizer Inc. Wins FDA Priority Review for Prostate Cancer Therapy
NEW YORK, July 22, 2026 Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Priority...
Pfizer
Advertisement
Chai Discovery Secures $400M to Transform AI Drug Discovery
SAN FRANCISCO, July 17, 2026 Chai Discovery has announced the successful completion of a $400 million Series C financing...
Pfizer Expands IBRANCE Label with New FDA Approval for HER2+ Breast Cancer
NEW YORK, June 24, 2026 Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved IBRANCE®...
Pfizer Partners with Chai Discovery to Accelerate AI-Powered Drug Discovery
SAN FRANCISCO, June 4 2026 Chai Discovery has announced a strategic license agreement with Pfizer that will enable the...
Pfizer Reports Landmark Seven-Year LORBRENA Data in Advanced ALK-Positive Lung Cancer
NEW YORK | May 29, 2026 Pfizer announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial, demonstrating...
Advertisements
Pfizer and Innovent Forge $10.5B Global Oncology Alliance
NEW YORK, SAN FRANCISCO, and SUZHOU, China, May 28, 2026 Pfizer Inc. and Innovent Biologics have announced a landmark...
Rigel Expands Oncology Portfolio With VEPPANU Licensing Deal
SOUTH SAN FRANCISCO, Calif., May 12, 2026 Rigel Pharmaceuticals has entered into an exclusive global licensing agreement with Arvinas...
Pfizer ELREXFIO Phase 3 Trial Improves Survival Outcomes
New York, United States | April 29, 2026 Pfizer Inc. has reported positive Phase 3 clinical trial results for...
Pfizer TALZENNA XTANDI Boost Survival in Prostate Cancer
NEW YORK, March 19, 2026 Pfizer Inc. announced that its Phase 3 TALAPRO-3 clinical trial evaluating TALZENNA® (talazoparib) in...
Pfizer Reports Positive Phase 2 Breast Cancer Results
New York, USA | March 17, 2026 Pfizer has announced positive topline results from its Phase 2 FOURLIGHT-1 clinical...
Advertisement
